



Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with persistent high triglycerides, EGFR <90 mL/min/1.73 m², and elevated high-sensitivity C-reactive protein ≥2.0 mg/L

February 28, 2002